0610025J13Rik Inhibitors
Chemical inhibitors of 0610025J13Rik operate through various mechanisms to disrupt its activity. Staurosporine is a potent kinase inhibitor that non-selectively targets a wide array of kinases which 0610025J13Rik may rely upon for its activity, leading to functional inhibition. Rapamycin, on the other hand, specifically inhibits mTOR, a key kinase within the PI3K/AKT/mTOR pathway which is essential for cellular functions that 0610025J13Rik may be involved in. By inhibiting mTOR, Rapamycin indirectly downregulates processes that are crucial for the activity of 0610025J13Rik. Similarly, LY294002 and Wortmannin are inhibitors of PI3K, critical to the PI3K/AKT signaling pathway. Inhibition of PI3K leads to reduced AKT phosphorylation and activity, resulting in diminished function of downstream proteins such as 0610025J13Rik.
In addition to PI3K inhibitors, PD98059 and U0126 target the MAPK/ERK pathway by inhibiting MEK. This inhibition prevents the downstream activation of ERK, which in turn can inhibit the function of proteins involved in this pathway, including 0610025J13Rik. SB203580 specifically inhibits p38 MAPK, disrupting the signaling pathway and consequently the activity of downstream proteins regulated by this pathway, such as 0610025J13Rik. SP600125, as a JNK inhibitor, disrupts the JNK signaling pathway, which is integral to various cellular processes, leading to the inhibition of proteins like 0610025J13Rik that are part of these processes. Bortezomib, a proteasome inhibitor, causes the accumulation of proteins destined for degradation, which can affect various signaling pathways and, by extension, the function of 0610025J13Rik. Lastly, tyrosine kinase inhibitors such as Dasatinib, Imatinib, and Sunitinib can inhibit a range of kinases, which leads to the functional inhibition of downstream signaling pathways and proteins, including 0610025J13Rik, by blocking the kinases they target.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine can inhibit 0610025J13Rik by non-selectively targeting a broad range of kinases that 0610025J13Rik may act upon, or require for proper function, leading to a functional inhibition of 0610025J13Rik's activity through kinase signaling interference. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR, a key kinase in the PI3K/AKT/mTOR pathway, which is essential for cell growth and proliferation. Since 0610025J13Rik plays a role in cellular processes, inhibition of mTOR can lead to downregulation of those processes, thereby inhibiting 0610025J13Rik. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 inhibits PI3K, which is crucial for the PI3K/AKT signaling pathway. Inhibition of PI3K can lead to reduced AKT phosphorylation and activity, resulting in a functional inhibition of downstream proteins including 0610025J13Rik. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is an inhibitor of PI3K, leading to the blockade of the PI3K/AKT pathway. This can functionally inhibit downstream effects mediated by this pathway, including the activity of 0610025J13Rik. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 inhibits MEK, which is part of the MAPK/ERK pathway. By inhibiting MEK, the downstream ERK phosphorylation and activation are prevented, which can lead to functional inhibition of proteins involved in this pathway, including 0610025J13Rik. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 selectively inhibits MEK1 and MEK2, which are upstream of ERK in the MAPK/ERK pathway. Inhibition of MEK activity can lead to decreased ERK signaling and thus can inhibit the function of downstream proteins such as 0610025J13Rik. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is an inhibitor of p38 MAPK. By inhibiting p38 MAPK, this chemical can disrupt the p38 MAPK signaling pathway, leading to functional inhibition of downstream proteins that are regulated by this pathway, including 0610025J13Rik. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits JNK, thereby disrupting the JNK signaling pathway. Since JNK pathway is involved in a myriad of cellular processes, inhibition of JNK can lead to the functional inhibition of proteins that are part of these processes, including 0610025J13Rik. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib inhibits the proteasome, leading to the accumulation of proteins that are destined for degradation. This can affect various signaling pathways and cellular processes, potentially leading to the functional inhibition of proteins such as 0610025J13Rik. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a tyrosine kinase inhibitor that can inhibit Src family kinases, c-Kit, and other kinases. Through the inhibition of these kinases, Dasatinib can functionally inhibit downstream signaling pathways and proteins, potentially including 0610025J13Rik. | ||||||